Spots Global Cancer Trial Database for bcl2 inhibitor plus im2 regimen
Every month we try and update this database with for bcl2 inhibitor plus im2 regimen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | NCT05576532 | T-lymphoblastic... Relapsed Diseas... Refractory Lymp... Refractory Leuk... Safety Efficacy, Self | BCL2 Inhibitor ... | 14 Years - 45 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
